Advertisement

Topics

Genentech’s Alecensa Beats Out Pfizer’s Xalkori in Late-Stage Lung Cancer Trial

20:00 EDT 16 May 2018 | BioSpace

Genentech, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer (NSCLC).

Original Article: Genentech’s Alecensa Beats Out Pfizer’s Xalkori in Late-Stage Lung Cancer Trial

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Alecensa Beats Out Pfizer’s Xalkori in Late-Stage Lung Cancer Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...